An initiative between BeOne Care Foundation and The Max Foundation has been renewed through 2028 to expand global access to zanubrutinib (Brukinsa) for patients with chronic lymphocytic leukemia in low- and middle-income countries. In a press release by BeOne Medicines, the company announced the continued collaboration, which builds on a partnership launched in 2023. The program is projected to support approximately 1,000 patients cumulatively.
To date, the initiative has enabled access to the treatment for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding its original scope by about 150 patients. Backed by a $1 million grant from the BeOne Care Foundation, the renewed agreement maintains this current care while expanding into regions like Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo, and Zambia, according to the company.
“We are thrilled to extend our collaboration with BeOne and the BeOne Care Foundation and further expand access to innovative treatment for people living with CLL in low- and middle-income countries,” Pat Garcia-Gonzalez, co-founder and CEO of The Max Foundation, said. “Working hand in hand with our partner physicians in Armenia, Ethiopia and Nepal we have been able to help hundreds of patients access treatment, enabling many of them to continue to support their families, spend time with loved ones and participate in their communities. We welcome BeOne Medicines and the BeOne Care Foundation’s shared commitment to expanding access to CLL treatment to more countries, patients and families, bringing dignity and hope to those in need.”
Leave feedback about this